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ASK A PATHOLOGIST 
 
Emily Coberly, MD, Krystal Tray, MT, and William Miller, MD 
University of Missouri– Columbia 
 
QUESTION:  A 53 years old female receives transfusion of 2 units of PRBCs.  One hour later, she 
develops acute dyspnea with decreased O2 saturations.  Chest x-ray demonstrates new bilateral 
pulmonary infiltrates.  Could this patient have TRALI? 
 
ANSWER: Yes, Transfusion Related Acute Lung Injury (TRALI) is an uncommon but extremely 
serious complication of blood product transfusion.  It can occur with transfusion of any blood products 
that contains plasma, including RBCs, FFP, whole blood, platelets, and cryoprecipitate.  The risk of 
TRALI is estimated to be between1:2000 and 1:5000 units of blood products; and TRALI is the leading 
cause of transfusion-related mortality. 
 
TRALI is most commonly caused by donor plasma containing anti-leukocyte antibodies, which react 
with neutrophils in the pulmonary micro-vasculature of the recipient, leading to increased vascular 
permeability and a pulmonary capillary leak syndrome resembling ARDS. 
 
By definition, TRALI occurs during or within 6 hours of transfusion of a plasma-containing blood 
product.  Symptoms include sudden onset of respiratory distress with clinical and x-ray evidence of 
acute bilateral pulmonary edema.  Hypotension and fever are often present.  TRALI is a diagnosis of 
exclusion and must be distinguished from the more common Transfusion Associated Circulatory 
Overload (TACO).  BNP and NT-pro-BNP levels can be elevated in both conditions and do not 
reliably distinguish between the two diagnoses.  As opposed to TACO, TRALI does not respond to 
diuretics.  Treatment of TRALI is supportive; symptoms typically resolve within 72 hours.   Mortality is 
5-10%. 
 
If you suspect a patient may have TRALI, it is extremely important to contact your pathologist or 
blood bank immediately.  Since TRALI is often caused by antibodies in donor plasma, the blood donor 
center must be contacted to quarantine any remaining products from the suspect donors.  Suspect 
donors are tested for anti-leukocyte antibodies, and donors implicated in an episode of TRALI are 
evaluated for continued eligibility to donate blood products. 
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Send your questions to coberlye@health.missouri.edu to be published in future editions of the Missouri Hospitalist. 
 
 
 
 
An Electrocardiogram that Tells  You All  You Need to Know 
 
 
 
 
This is a 66 year old woman with progressive dyspnea on exertion for 7 months.  Based 
on the ECG findings, what further evaluation is indicated? 
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